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Brief Report
Summary
Objectives: The aim of the study was to obtain an overview on 
diagnostic and therapeutic activities concerning hepatitis A, B, 
C virus and HIV in Swiss prisons. 
Methods: A standardized questionnaire was sent to 91 prisons 
in the German and Italian speaking parts in October 2004; 41 
institutions (45 %) answered the questionnaire.
Results: In almost all prisons serological examinations were not 
done routinely, but were provided when demanded by inmates 
or recommended by the medical service. Vaccination against 
hepatitis A or B infection and initiation of antiviral therapy 
was possible in most institutions. 
Conclusions: Most of the prisons investigated offered diagnos-
tic and antiviral treatment for hepatitis virus and HIV infec-
tions. A reported problem was the discontinuation of ongoing 
treatments or vaccination cycles after discharge. In some cases 
deficient funding was an obstacle.
Keywords: Hepatitis A virus infections – Hepatitis B virus infections – 
Hepatitis C virus infections – Inmates – Prisons. 
Switzerland has approximately 170 prisons, 24 of which are 
for incarceration periods longer than six months. In 2003, 
5266 persons were arrested. Among these, 2637 persons 
(50 %) were not yet sentenced: 1710 in pretrial detention, 301 
awaiting repatriation and 626 in other forms of custody1. 
International studies have reported seroprevalence rates in 
 incarcerated persons of 1.2 to 6.6 % HIV2-5, 22 and 49 % hepa-
titis C virus (HCV) and 6 to 25.2 % resolved or ongoing he-
patitis B virus (HBV) infection2, 3, 5, 6. Despite these significant 
rates, there is currently no federal ordinance on the prevention, 
diagnosis and treatment of HIV and hepatitis virus infections 
in Swiss prisons7. Recently guidelines have been deemed nec-
essary by experts8. In Switzerland no extensive HIV or HCV 
prevalence studies in the correctional setting are available. One 
of the aims of our study was to estimate the recent prevalence 
of HIV and HCV infections on the basis of staff information. 
The main goal of this survey was to report on the present provi-
sion of screening and treatment for serious infectious diseases 
like HIV and HCV infections in Swiss correctional facilities.
Methods
Study population
This study targeted pretrial detention penitentiaries and facili-
ties, in the German and Italian speaking parts of Switzerland. 
Institutions for inmates exclusively awaiting repatriation to 
their country of origin were not included in this study, nor 
were 24 French speaking facilities. Addresses of all institu-
tions included in the study were provided by the Swiss Fed-
eral Statistical Office. 
A questionnaire was sent to the directors of the correctional 
facilities on October 18, 2004. It consisted of two parts: i) 
Screening and treatment of HIV, hepatitis virus infections and 
TB and ii) preventive measures provided for HIV and HCV. 
The findings from the second section have already been pub-
lished9. A standardized reminder letter was sent to non-re-
sponding institutions four weeks after the initial letter. Of the 
91 facilities contacted, 63 responded. 22 institutions (24 %) 
stated in a short note that a lack of time hindered them in 
answering the questionnaire. 41 institutions returned a ques-
tionnaire, resulting in a response rate of 45 % (41/91) for the 
survey period running from October to the end of December 
2004. 
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Medical staff and directors each answered 37 % of the ques-
tionnaires (15/41), and 9 % (4) were completed by others 
(e.g. direction social service). As it was optional to provide 
respondent details (such as profession), this contributed to the 
lack of information on the professional background in 17 % 
of the questionnaires (7/41). Our instructions did not limit 
answers to only medical staff; directors could choose to fill 
out the questionnaires themselves or pass them on to the ap-
propriate personnel. 
Statistical analysis
Returned questionnaires were entered into SPSS 11.5 using a 
double data entry procedure. Differences in proportions were 
tested by Chi-square statistics. The risk of type I error was 
set to 0.05 and, due to the exploratory nature of this study, 
was not adjusted for multiple testing. Percentages were given 
using an item-wise exclusion of missing values. Thus, the re-
ported N varies in the description of the results. 
Results
We asked the staff about the type and size of their correctional 
facility. 24 of the responding institutions provided places for 
sentenced and pretrial detention for men, 19 institutions had 
pretrial detention places for women and 9 facilities had places 
for sentenced women. A total of 2540 places were represented 
by all responding institutions. At the time of the study, 2443 
places were occupied (96 %). Half of the institutions reported 
a capacity less than 36 places, and three quarters of the insti-
tutions reported a capacity of less than 79 places (range 5–462 
places).
Estimated prevalence of HIV and HCV
The staff of the facilities were asked to report the prevalence 
of HIV and HCV among the inmates, using established re-
porting systems or to estimate the prevalence rates based on 
their experience. For HIV, the weighted mean of the preva-
lence rates was 2.5 % (CI 2.0–2.9). This number was equally 
based on estimations and on actual serological tests, which, 
however, referred to known cases and were usually not based 
on routine screening. The weighted mean of HCV prevalence 
rates was 7.0 % (CI 6.2–7.8). The reported prevalence rates 
were based on estimations in about 60 % of the facilities and 
in about 40 % on identified cases.
Screening
Almost all institutions (39/40) offered HIV, HBV and HCV 
serological testing. In 3 institutions inmates could not be test-
ed for HAV; we have no explicit information why this was 
so. The main reasons reported for not conducting serologi-
cal examinations (aside from denied patient consent) were a 
lack of internal medical services (6/23) and an absence of any 
medical examination (8/26). Other reasons included insuffi-
cient cost coverage (3) and short periods of incarceration (2). 
Moreover, it was mentioned that in some cases, tests of earlier 
institutions were consulted (1) and that the effort and the con-
sequences of testing were not clear (1). 
In 63 to 88 % of the institutions, serological tests were done 
on the request of the inmate, and in 46.2 to 61 % on the rec-
ommendation from the prison doctor. Routine serological 
testing for HIV, HBV and HCV for all consenting inmates 
was done in only one institution. No institution routinely 
tested for HAV.
Treatment
In 90 % (36/40) of the institutions the inmates had the oppor-
tunity to receive HIV antiviral therapy. For chronic HCV and 
chronic HBV infections, 34 and 35 out of 40 institutions, of-
fered antiviral therapy respectively (85 % and 88 %). Of the 6 
institutions that stated that it was not possible to provide treat-
ments for all chronic infections, 3 stated that they transferred 
patients to other places when such treatments are necessary, 
while 2 others stated that the continuation of a treatment is 
possible, but that they normally do not initiate it; one institu-
tion did not comment on this.
In all facilities, the diagnosis from the presiding doctor is re-
quired to initiate pharmacotherapy (35/35). In three institu-
tions, a stay between 6 and 12 months was also a condition for 
initiating the treatment for chronic hepatitis virus infection. 
In addition, two institutions also mentioned an incarceration 
period of more than 6 months as a necessary condition for 
initiating the treatment for HIV.
Possible reason Chronic hepatitis virus infection HIV infection
n (valid %) n missing values n (valid %) n missing values
No internal health service 4 (22) 23 3 (18) 24
No covering of the costs 5 (25) 21 3 (17) 23
No external health service 3 (17) 23 3 (18) 24
Table 1. Reasons for not 
initiating a pharmaceutical 
therapy in eligible patients 
N = 41.
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Reasons for not offering pharmaceutical therapy are shown in 
table 1. For hepatitis virus infections, funding problems were 
an obstacle for starting an antiviral therapy in more institu-
tions than for HIV. 
In 33/38 institutions (87 %) patients who started antiviral ther-
apy during imprisonment were transferred to continuing treat-
ment programs after being released: As an open question, the 
reasons for not arranging a transfer to a continued treatment 
place were asked for. A reason mentioned by 4 institutions 
was that the incarcerated person was considered responsible 
to contact a medical service himself after release. Another re-
sponse was that the maintenance of therapy is difficult when 
the inmate is homeless or has no family doctor. Other reasons 
included the absence of legal regulations, repatriation outside 
Switzerland (transfer in such cases is sometimes not possible) 
and a too short period of imprisonment.
Vaccinations against HAV and HBV
Most of the institutions provided vaccinations against hepati-
tis A (30/39, 77 %) and hepatitis B (32/40, 80 %). They were 
provided through either the request of the inmate (26/29) or 
the prison doctor’s recommendation (26/32). 
There are different agencies supporting vaccinations finan-
cially (table 2). In most institutions, health insurance is men-
tioned as a possible funding source (27/29, 93 %). In 9/24 in-
stitutions (38 %) the inmates themselves have to pay the costs 
in some cases. 
The main reason for not providing vaccinations, after inmate 
rejection, was that the costs were not covered. This was stated 
by 6/28 institutions (21 %). A shortage of staff was also men-
tioned in 2/27 institutions (7 %). Further reasons mentioned 
included the lack of medical employees in the institution (2), 
an insufficient number of infected persons over the years (1), 
no explicit recommendation (1), no indication (1), and too 
short of an imprisonment period (4).
If a cycle of vaccination (two doses for HAV and three doses 
for HBV) was initiated but unfinished at discharge, 24/36 in-
stitutions (67 %) transferred their inmates to a service where 
the vaccination cycle could be finished. However, for 12 in-
stitutions (33 %) this was not the case. The reasons for not 
transferring an inmate are similar to the situation with initi-
ated therapies. 
In order to ensure the transfer after discharge, one institution 
mentioned that the effort of the prison staff to find an appro-
priate treatment place should be financed. Also, searching for 
a doctor who is willing to continue treatment has been identi-
fied as a “tedious” process.
Discussion
In this study, 41 Swiss prisons  answered our questionnaire. 
It is not known in all cases who answered the questionnaire, 
i.e. medical doctors, directors or other professions. Yet due to 
the general nature of the questions this should not have gener-
ated significant inaccuracy. Achievements as well as deficits 
were reported. However, it remains uncertain whether the 
findings for the participating institutions can be extended to 
those who did not respond, or were not included (24 institu-
tions in the French speaking region). It is also possible that 
questionnaires may have been rejected in order to avoid the 
exposure of an unfavorable situation, however there was no 
indication for this. Despite these limitations, this study gives 
a first overview, and may be helpful for further research on 
this important topic.
The staff of the prisons questioned estimated HIV and HCV 
infections to be quite frequent among their inmates (preva-
lence rates 2.5 % for HIV and 7 % for HCV infections). 
Compared to inmate populations in other countries, this 
prevalence seems to be lower, especially for HCV infec-
tions. However, a noted limitation of this data is that it is 
based on estimated prevalence rates and not on systematic 
surveys with serological testing of all inmates. In almost all 
responding institutions, tests for hepatitis A, B and C virus 
and HIV infections were available, but testing was primarily 
done only if requested by the inmate or recommended by 
the prison doctor. Thus, the prevalence rates may have been 
underestimated. 
Most of the institutions were able to provide antiviral therapy 
for HIV or chronic hepatitis B or C infection, however others 
Funding agency Yes No
n (valid %) n (valid %) n missing values
Health insurance 27 (93) 2 (7) 12
Cantonal department 
of justice
17 (59) 12 (41) 12
Facility 12 (56) 14 (44) 15
Inmate pays   9 (38) 15 (62) 17
Table 2. If vaccinations are 
performed (HBV, HAV), who is 
paying them?
(More than one funding 
source is possible) N = 41.
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did not due to a lack of doctors, or because the costs were 
not covered. However, to draw clear conclusions concerning 
insufficient medical staff or funding for therapies, more spe-
cific information on the special situations has to be collected. 
Standards of the Council of Europe require that inmates have 
access to medical care equal to that of patients in the outside 
community10, 11. Nevertheless, it seems reasonable that in in-
stitutions where inmates only stay short time (e.g. transitional 
sentence) longterm antiviral therapy is not initiated when 
there is no acute need.  
Of the institutions questioned, 77 % respectively 80 % offered 
vaccinations against HAV and HBV. The main reason why 
vaccinations were not always carried out was the  lack of staff 
or funding. Furthermore, it was stated that explicit guidelines 
for vaccinations in Swiss prisons do not exist. Indeed, Swit-
zerland has no recommendation to vaccinate prisoners against 
hepatitis A or B 12-14. The maintenance of an already-initiated 
antiviral therapy or the completion of a vaccination cycle af-
ter release of an inmate is still unsatisfactory in Swiss pris-
ons. This situation can only be improved if health institutions 
within and outside of the prison establish procedures on how 
to cooperate, exchange information on the inmates, and reach 
an agreement on cost coverage. There is an urgent need to 
increase awareness on these issues and to identify where rec-
ommendations are needed.
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